|
ACADIA Pharmaceuticals puts genes and drugs together to fight disease. The development-stage company uses its proprietary R-SAT technology to identify genomic targets for its small-molecule (chemical) drug therapies, primarily for central nervous system disorders. ACADIA hopes its lead drug candidate pimavanserin (under development with Biovail) will effectively treat psychosis in patients with Parkinson's disease. In partnership with eye-care heavyweight Allergan, ACADIA is also developing therapies for glaucoma and chronic pain. Other development targets include neurological indications such as insomnia and schizophrenia.
|
| | | Contact Information | |
Address: |
3911 Sorrento Valley Blvd.
San Diego, CA 92121-1402
| | Phone: | 858-558-2871 | | Fax: | 858-558-2872 |
|
| Financial
Highlights | | Fiscal Year End: | December | | Revenue (2008): | 1.60 M | | Revenue Growth (1 yr): | (-79.00%) | | Employees (2008): | 63 | | Employee Growth (1 yr): | (-55.90%) |
|
|
Key People
| | • |
Chairman:
Leslie L. Iversen
| | • |
CEO and Director:
Uli Hacksell
| | • |
VP, CFO, Secretary, and Treasurer:
Thomas H. Aasen
|
|
|
